Welcome to our dedicated page for Tactile Systems news (Ticker: TCMD), a resource for investors and traders seeking the latest updates and insights on Tactile Systems stock.
Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD) is a medical technology company that develops and markets at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. This news page aggregates company announcements, financial updates and clinical data releases related to TCMD stock and its underlying business.
Investors and healthcare observers can find earnings releases and quarterly financial results, where Tactile Medical reports revenue from its lymphedema and airway clearance product lines, along with metrics such as gross margin, operating income, net income and Adjusted EBITDA as defined by the company. These updates often include commentary on business priorities, share repurchase activity and outlook ranges for full-year revenue and Adjusted EBITDA.
The news flow also features clinical and scientific developments, including randomized controlled trial data on Flexitouch Plus for head and neck cancer-related lymphedema. Company press releases describe symptom improvements, swelling reduction and quality-of-life outcomes associated with its advanced pneumatic compression devices, as well as presentations at major medical meetings such as the American Society of Clinical Oncology and the American Congress of Rehabilitation Medicine.
In addition, this page includes notices of upcoming conference calls, investor conference presentations and other corporate events. Readers following TCMD news can use this feed to monitor how Tactile Medical communicates its strategy in at-home therapies, its collaboration with clinicians and durable medical equipment partners, and its efforts to expand access to care for patients with chronic lymphatic and pulmonary disorders. Bookmark this page for a centralized view of Tactile Systems Technology’s latest press releases and public disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Tactile Systems Technology, Inc. (TCMD) will release its financial results for the first quarter of fiscal year 2023 on May 8, 2023, before market open.
Management will host a conference call at 5:00 p.m. ET to discuss these results, available via phone and live webcast. Tactile Medical specializes in therapies for chronic disorders like lymphedema and chronic pulmonary disease, focusing on enhancing patient care and reducing healthcare costs. The company's commitment to improving quality of life continues as it collaborates with clinicians to expand clinical evidence and access to care.
Tactile Systems Technology (TCMD) announced the appointment of Elaine Birkemeyer as Chief Financial Officer, effective March 20, 2023. She succeeds Brent Moen, who is retiring. With over 25 years of experience in finance and leadership roles at Fortune 500 companies, Birkemeyer is expected to contribute significantly to Tactile's growth strategy. She previously held key positions at UnitedHealth Group and Best Buy. The company emphasizes its leadership in at-home therapies for chronic conditions, highlighting a large addressable market and a recently strengthened financial position.
Tactile Systems Technology (Nasdaq: TCMD) has announced its participation in two upcoming virtual investor conferences:
- 33rd Oppenheimer Annual Healthcare Conference on March 13-15, with a fireside chat scheduled for March 13 at 12:40 p.m. ET.
- Sidoti Small-Cap Conference on March 22-23, with management presenting on March 22 at 2:30 p.m. ET.
Live audio webcasts of the presentations will be accessible on the company's investor relations website, along with archived replays post-conference. Tactile Medical focuses on therapies for chronic conditions, enhancing care and quality of life for patients.
Tactile Medical (TCMD) has announced a public offering of 2,500,000 shares of common stock at $13.00 per share, aiming to raise approximately $32.5 million before expenses. The underwriter, William Blair & Company, has a 30-day option to purchase an additional 375,000 shares. Proceeds from the offering will be used for expanding commercial activities, funding milestone payments, supporting new product development, and enhancing reimbursement coverage. The offering is expected to close by February 28, 2023, subject to customary conditions. This offering is conducted under a previously filed shelf registration statement with the SEC.
Tactile Medical (Nasdaq: TCMD) announced its intention to conduct an underwritten public offering of its common stock, granting underwriters a 30-day option to purchase an additional 15% of shares offered. The proceeds will fund various initiatives, including expanding commercial activities, supporting new product development, and potential acquisitions. The offering is under a shelf registration effective since January 25, 2023. William Blair & Company is the sole book-running manager. The offering is subject to market conditions, and Tactile Medical cautions investors about forward-looking statements regarding the offering and its business prospects.
Tactile Systems Technology, Inc. (TCMD) reported a 20% increase in fourth quarter revenue to $73.9 million, driven by strong performances in both lymphedema and airway clearance products.
The full-year revenue rose 19% to $246.8 million. Lymphedema product revenue grew 5%, while airway clearance products surged 90% to $34.5 million for the year.
Despite operational improvements, the company recorded a net loss of $17.9 million for 2022. Looking ahead, TCMD projects a revenue increase of 9% to 11% for 2023, totaling between $269.0 million and $273.0 million.